Related Experiment Videos
Advances in the treatment of urothelial tract tumors
Abstract:
Recently developed combination chemotherapy programs have now produced durable complete remissions in a significant percentage of patients with advanced urothelial tract malignancies. For advanced disease, efforts must still be directed at developing new agents but must also focus on understanding drug resistance. Some tumors appear to be resistant de novo; others respond for a period of time before a resistant population emerges. Clearly multiple factors come into play. In some cases, pharmacologic factors such as bioavailability metabolism, or toxicities predominate. In other cases, specific genes expressing surface proteins such as the p-glycoprotein identified in resistant ovarian tumors have been implicated. In the 1980s, it is no longer adequate to define tumors simply by pathologic inspection. As demonstrated by Russell and co-workers xenografts of phenotypically similar transitional cell tumors in nude mice demonstrated marked heterogeneity with respect to flow cytometric DNA analysis and immunocytochemistry. With the recent adoption of flow cytometric techniques, both from bladder washings and paraffin sections, insight into the biologic behavior of individual tumors may soon be possible. Blood group antigen expression and monoclonal antibodies to tumor-associated antigens may also help in this regard. For primary tumors, attention is now being focused on protocols aimed at bladder preservation. In some cases, radiation therapy alone can produce long-term survival, despite muscle infiltrating disease. Complete remissions have also been described with chemotherapy alone. The interaction of chemotherapy and radiation therapy has only recently begun to be investigated. In these trials, complete local control must still be the primary goal. Standard criteria for staging and response evaluation, including pathologic documentation of remission status, are crucial. To demonstrate a beneficial effect of therapy, long-term randomized trials will be required. The goal of individualized therapies may soon be possible, which will ideally translate into increased clinical benefit for patients with urothelial tract tumors.
Insights
Advanced urothelial tract tumors show promise with new chemotherapy, but understanding and overcoming drug resistance is crucial. Future research aims for individualized therapies to improve patient outcomes.
Area of Science:
- Oncology
- Urothelial Carcinomas
- Cancer Drug Resistance
Background:
- Combination chemotherapy has improved outcomes for advanced urothelial tract malignancies.
- Drug resistance, either intrinsic or acquired, remains a significant challenge in treating these cancers.
- Tumor heterogeneity, previously underestimated, complicates treatment strategies.
Purpose of the Study:
- To explore the multifaceted nature of drug resistance in advanced urothelial tract tumors.
- To highlight the importance of understanding tumor biology beyond traditional pathology.
- To discuss emerging diagnostic and therapeutic approaches for urothelial cancers.
Main Methods:
- Review of recent advancements in combination chemotherapy for urothelial malignancies.
- Discussion of pharmacologic and genetic factors contributing to drug resistance.
- Exploration of flow cytometry, antigen expression, and monoclonal antibodies for tumor characterization.
- Consideration of bladder preservation strategies involving chemotherapy and radiation therapy.
Main Results:
- Durable complete remissions are achievable with current combination chemotherapy.
- Drug resistance mechanisms are diverse, involving pharmacologic factors and specific gene expressions (e.g., p-glycoprotein).
- Flow cytometry and immunocytochemistry reveal significant tumor heterogeneity.
- Bladder preservation protocols combining chemotherapy and radiation show potential.
Conclusions:
- Overcoming drug resistance is paramount for improving treatment efficacy in advanced urothelial cancers.
- Advanced techniques like flow cytometry offer deeper insights into tumor biology.
- Individualized therapeutic approaches hold the promise of increased clinical benefit for patients.